Management of Visceral Pancreatic Cancer Pain

Rationale for TCA Selection

• The American Society of Clinical Oncology recommends TCAs, such as nortriptyline and duloxetine, as adjuvant medications for pancreatic cancer pain with neuropathic components due to tumor proximity to the celiac axis 1
• The NCCN guidelines list tricyclic antidepressants, including amitriptyline, imipramine, nortriptyline, and desipramine, as coanalgesics for neuropathic pain components in cancer patients 2

Specific TCA Recommendation

• Nortriptyline should be started at 10-25 mg nightly and increased every 3-5 days to 50-150 mg nightly as tolerated 2
• Nortriptyline is better tolerated than tertiary amines like amitriptyline, with fewer anticholinergic adverse effects 2

Integration with Current Regimen

• The TCA will complement the existing opioid and gabapentin regimen by targeting the neuropathic component of visceral pain 1, 2
• Gabapentin addresses neuropathic pain through calcium channel modulation, while TCAs work through norepinephrine and serotonin reuptake inhibition plus sodium channel blockade 2

Important Caveats

• Titrate slowly in elderly or medically frail patients to minimize side effects 2
• Monitor for anticholinergic effects, including constipation, urinary retention, confusion, and orthostatic hypotension 2
• If TCAs are contraindicated or not tolerated, duloxetine is an alternative SNRI with evidence for neuropathic pain 1, 2